AFM 24
Alternative Names: AFM-24; EGFR/CD16A ICE®Latest Information Update: 17 Jul 2026
At a glance
- Originator Affimed Therapeutics
- Developer Affimed Therapeutics; NKGen Biotech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; Phagocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 14 Jul 2026 XOMA has been acquired by Ligand Pharmaceuticals
- 06 Sep 2025 Updated efficacy and adverse events data from the phase I/II AFM24-102 trial in Solid tumours presented at the 26th World Conference on Lung Cancer (WCLC-2025)
- 30 May 2025 Updated efficacy and adverse events data from the phase I/II AFM24-102 trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)